Randomized trial shows Vitamin C improves survival rates in precancerous blood disorder patients — Evidence Review
Published in Cancer, by researchers from Van Andel Institute, Stand Up To Cancer, University of Copenhagen
Researched by
— the AI search engine for science
Table of Contents
A new randomized trial suggests that restoring vitamin C levels in people with certain precancerous blood disorders may reduce adverse events and is associated with a potential survival benefit. Most prior studies support a possible biological effect of vitamin C on leukemia risk and progression, though results across cancer and sepsis populations are mixed. The new findings from the Van Andel Institute add to a growing body of research exploring vitamin C’s role in early blood disorders.
- Several studies indicate that vitamin C deficiency is common among leukemia patients and that supplementation may help restore enzymatic activity involved in controlling abnormal blood cell growth, particularly via TET2 pathways 1 5 12 13.
- While in vitro and animal studies suggest high-dose or intravenous vitamin C can inhibit leukemia cell proliferation and modulate immune and inflammatory responses, clinical evidence from randomized trials remains limited and sometimes inconsistent 2 4 8 9 14.
- Some research highlights that vitamin C supplementation is safe and may improve certain clinical outcomes in specific patient subgroups, but more rigorous, larger-scale studies are needed to confirm survival benefits and clarify optimal dosing and patient selection 8 9 14.
Study Overview and Key Findings
The EVITA phase 2 trial addresses a significant gap in preventive strategies for people with early-stage blood disorders that can progress to acute myeloid leukemia (AML). Most individuals with conditions such as clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS) currently have no effective preventive therapies, often facing a "watch and wait" approach. This study is notable for its focus on correcting vitamin C deficiency with oral supplementation, rather than high-dose intravenous administration, and for its exploration of potential biological and survival effects in a pre-leukemic population.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Van Andel Institute, Stand Up To Cancer, University of Copenhagen |
| Journal Name | Cancer |
| Authors | Stine Ulrik Mikkelsen, Ali Al-Mousawi, Amalie Bach Puglisi, Anders Pommer Vallentin, Astrid Østergaard Mortensen, Zachary Madaj, Toshinori Hinoue, Heidi Naomi Ottesen, Jakob Schmidt Jespersen, Linn Gillberg, Morten Tulstrup, Niels Richard Hansen, Jakob Werner Hansen, Mette Klarskov Andersen, Stacey Lyn Thomas, Christine Isaguirre, Ryan Sheldon, Marie Adams, Ryan Burgos, Stephen Baylin, Bo Kok Mortensen, Casey Lee O’Connell, Marianne Tang Severinsen, Peter William Laird, Jens Lykkesfeldt, Peter Jones, Kirsten Grønbæk |
| Population | People with precancerous blood disorders |
| Sample Size | n=109 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Changes in inflammation, survival rates |
| Results | Vitamin C group had higher survival rates after three years. |
Literature Review: Related Studies
To place the new findings in context, we searched the Consensus paper database, which includes over 200 million research articles. The following search queries were used to identify relevant related studies:
- vitamin C leukemia prevention
- survival rates vitamin C treatment
- leukemia outcomes vitamin C supplementation
Below is a summary of key topics and findings from the literature:
| Topic | Key Findings |
|---|---|
| Does vitamin C influence leukemia development or progression? | - Vitamin C deficiency is common in AML and MDS patients at diagnosis, with levels returning to normal after remission 5. - Vitamin C supplementation supports TET2 enzyme activity, which may limit abnormal blood cell growth and could be especially relevant in TET2-mutated cases 1 12 13. |
| What is the clinical impact of vitamin C supplementation in cancer? | - Vitamin C supplementation is generally safe and may improve quality of life and, in some studies, progression-free survival or specific outcomes in select cancers, but evidence for overall survival benefit is inconsistent 8 9 14. - Some studies suggest a synergistic effect with chemotherapy, especially in certain subgroups or mutation types 12 14. |
| How does vitamin C affect inflammation and immune signaling in leukemia? | - Vitamin C can reduce inflammatory cytokine production and modulate immune response in leukemia cell lines, potentially contributing to anti-leukemic effects 4. - Molecular studies show that vitamin C may suppress cell proliferation and tumor growth partly by targeting inflammatory and cell signaling pathways 3 4. |
| Are there risks or limitations to vitamin C supplementation in cancer? | - Vitamin C may antagonize the cytotoxic effects of some antineoplastic drugs in vitro, potentially reducing therapeutic efficacy if given simultaneously with certain chemotherapies 11. - Evidence from sepsis trials is mixed, with some showing no mortality reduction or even potential harm when vitamin C is given intravenously in critical illness 6 7 10. |
Does vitamin C influence leukemia development or progression?
Multiple studies support the observation that vitamin C deficiency is prevalent in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and that vitamin C is involved in key enzymatic processes—particularly TET2 activity—that may suppress leukemic transformation. The current trial's focus on correcting deficiency aligns with this biological rationale.
- Vitamin C levels are significantly lower in AML patients at diagnosis and appear to increase with remission, suggesting a link between vitamin C status and disease activity 5.
- Restoration of TET2 activity by vitamin C has been demonstrated in cell studies, but is dependent on the expression of vitamin C transporters such as SLC2A3 and GLUT3 1 13.
- Some studies identify vitamin C supplementation as particularly relevant in TET2-mutated or transporter-competent patient subsets, which may inform future personalization of therapy 1 13.
- While biological plausibility is strong, clinical benefits for leukemia prevention or slowing progression remain to be confirmed in larger, prospective trials 5 12 13.
What is the clinical impact of vitamin C supplementation in cancer?
Clinical studies and systematic reviews generally find vitamin C supplementation to be safe in cancer patients, with some evidence for improved quality of life, infection rates, or survival in certain subgroups. However, robust survival benefits have not been consistently observed across randomized trials, and effects may depend on route of administration (oral vs. intravenous), dosage, and patient characteristics.
- Systematic reviews indicate that vitamin C may have a positive effect on cancer survival or progression-free survival in specific contexts, but highlight the need for more rigorous randomized controlled trials 8 9.
- Supplementation during intensive chemotherapy was associated with fewer infections and improved survival in patients with NPM1-mutated AML, but not in unselected populations 14.
- Low-dose intravenous vitamin C combined with hypomethylating agents like decitabine showed synergistic effects and improved remission rates in elderly AML patients 12.
- Clinical impact on overall survival in unselected populations remains uncertain, with the new study providing preliminary evidence for a survival signal in pre-leukemic disorders 8 9 14.
How does vitamin C affect inflammation and immune signaling in leukemia?
Laboratory studies demonstrate that vitamin C can modulate inflammatory signaling, reduce pro-inflammatory cytokines, and affect immune cell function. The new study’s finding of altered cytokine levels in the vitamin C group is consistent with these laboratory observations.
- Vitamin C reduces interleukin-6 (IL-6) and tumor necrosis factor (TNF) production and increases anti-inflammatory cytokines such as interleukin-10 (IL-10) in leukemia cell lines 4.
- Molecular docking and pathway analysis studies indicate that vitamin C targets key regulators of cell proliferation and apoptosis, such as TP53 and MAPK1 3.
- Vitamin C’s effect on purinergic signaling and autophagy pathways may contribute to anti-inflammatory and anti-leukemic effects in vitro 4.
- These immunomodulatory actions complement its epigenetic effects and may underlie clinical benefits observed in some studies 3 4.
Are there risks or limitations to vitamin C supplementation in cancer?
While generally safe, some in vitro studies raise concerns that vitamin C may reduce the efficacy of certain chemotherapy agents by protecting cancer cells from apoptosis. Clinical trials in sepsis and critical illness have yielded mixed results, with some suggesting no benefit or even harm with intravenous vitamin C.
- Pretreatment with vitamin C may antagonize the effects of several antineoplastic drugs in leukemia and lymphoma cell lines, though clinical relevance remains uncertain 11.
- In randomized trials of intravenous vitamin C for sepsis, results were mixed: one study found reduced mortality, while another showed increased risk of death or organ dysfunction 6 7 10.
- These findings highlight the importance of timing, dosing, and patient selection when considering vitamin C as an adjunct to chemotherapy or in critically ill patients 10 11.
- The new study did not find significant adverse effects of oral vitamin C, suggesting safety in the studied pre-leukemic population 6 7 10 11.
Future Research Questions
While the new study provides important preliminary evidence for the potential benefits of vitamin C supplementation in early blood disorders, further research is needed to clarify its role in leukemia prevention, identify optimal dosing strategies, and determine which patient groups are most likely to benefit. Larger phase 3 trials and mechanistic studies will be essential to address these questions.
| Research Question | Relevance |
|---|---|
| Does oral vitamin C supplementation reduce leukemia incidence or delay progression in high-risk populations? | Determining whether vitamin C can actually prevent or delay leukemia onset in at-risk groups is critical for its use as a preventive therapy 5 8. |
| Which biological mechanisms mediate the effects of vitamin C in pre-leukemic disorders? | Understanding the precise molecular and cellular pathways—such as TET2 activation and inflammatory modulation—could guide targeted interventions 1 3 4 12 13. |
| Are there genetic or molecular biomarkers that predict response to vitamin C supplementation in leukemia or pre-leukemia? | Identifying biomarkers such as TET2 mutation or SLC2A3/GLUT3 expression may help personalize therapy and select patients most likely to benefit 1 5 13 14. |
| How does the route and dose of vitamin C (oral vs. intravenous) impact clinical outcomes in leukemia patients? | Clarifying the optimal administration method and dosing is important, as studies suggest different effects for oral vs. intravenous vitamin C 2 8 9 12. |
| Does vitamin C supplementation interfere with the effectiveness of standard chemotherapy in leukemia? | Some laboratory studies suggest possible antagonism between vitamin C and chemotherapeutic agents, warranting careful evaluation in clinical contexts 11 12 14. |